Contraceptive Research and Development: Looking to the Future
Polly F. Harrison, Allan Rosenfield
National Academies Press, Nov 4, 1996 - Health & Fitness - 519 pages
The "contraceptive revolution" of the 1960s and 1970s introduced totally new contraceptive options and launched an era of research and product development. Yet by the late 1980s, conditions had changed and improvements in contraceptive products, while very important in relation to improved oral contraceptives, IUDs, implants, and injectables, had become primarily incremental. Is it time for a second contraceptive revolution and how might it happen?
Contraceptive Research and Development explores the frontiers of science where the contraceptives of the future are likely to be found and lays out criteria for deciding where to make the next R&D investments.
The book comprehensively examines today's contraceptive needs, identifies "niches" in those needs that seem most readily translatable into market terms, and scrutinizes issues that shape the market: method side effects and contraceptive failure, the challenge of HIV/AIDS and other sexually transmitted diseases, and the implications of the "women's agenda."
Contraceptive Research and Development analyzes the response of the pharmaceutical industry to current dynamics in regulation, liability, public opinion, and the economics of the health sector and offers an integrated set of recommendations for public- and private-sector action to meet a whole new generation of demand.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
abortion acrosome reaction activity Alan Guttmacher Institute antibodies antigen antiprogestins barrier binding Biology cells ceptive cervical clinical trials committee condom contraceptive methods contraceptive research contraceptive technologies costs cycle developing countries drug efficacy emergency contraception endometrium epididymis estrogen factor family planning female fertility follicle formulation funding gene genital GnRH hormone immunocontraceptive immunogen Immunology implantation induce industry infection infertility inhibition Institute of Medicine Journal male manufacturers Medical meiosis membrane menstrual menstrual cycle mice mifepristone million molecular mouse mucosal Norplant oral contraceptives Organization ovulation peptide percent pharmaceutical pill Population potential pregnancy prevent progesterone progestin Program protection protein Public Health receptor regulation Reproductive Health reproductive tract research and development risk Science sexually transmitted diseases side effects specific sperm spermatogenesis spermicides STDs sterilization steroid studies target tion tive UNFPA unintended pregnancy United users uterus vaccine vaginal WHO/HRP women Women's Health York zona pellucida